Cancer Letters
Volume 291, Issue 2 , Pages 237-245, 28 May 2010

Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8

Department of Biology, Boston University, Boston, MA 02215, USA

Received 13 August 2009; received in revised form 22 October 2009; accepted 26 October 2009. published online 30 November 2009.

Abstract 

Human c-Rel (REL) is a member of the NF-κB family of transcription factors. REL’s normal physiological role is in the regulation of B-cell proliferation and survival. The REL gene is amplified in many human B-cell lymphomas and overexpression of REL can transform chicken lymphoid cells. In this report, histone acetyltransferase p300 enhanced REL-induced transactivation and interacted with REL both in vitro and in REL-transformed chicken spleen cells and the B-lymphoma cell line RC-K8, in which REL is constitutively active and required for proliferation. However, due to a deletion in the EP300 locus, only a C-terminally truncated form of p300 is expressed in RC-K8 cells. These results suggest a role for p300 in REL-mediated oncogenic activity in B lymphoma.

Abbreviations: aa, amino acid(s), DLBCL, diffuse large B-cell lymphoma, FLAG, flu antigen, NLS, nuclear localization signal, NRG, non-REL gene, RHD, Rel homology domain, qPCR, quantitative polymerase chain reaction, RT-PCR, reverse transcriptase-PCR, TAD, transactivation domain

Keywords: c-Rel, p300, CBP, RC-K8, Diffuse large B-cell lymphoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(09)00656-9

doi:10.1016/j.canlet.2009.10.018

Cancer Letters
Volume 291, Issue 2 , Pages 237-245, 28 May 2010